Oppenheimer Maintains Outperform on Incyte, Lowers Price Target to $84
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Incyte (NASDAQ:INCY) but lowers the price target from $92 to $84.
April 24, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer maintains an Outperform rating on Incyte but lowers the price target from $92 to $84.
While the reduction in price target could suggest a tempered outlook on Incyte's short-term price potential, the maintenance of an Outperform rating indicates a continued positive view on the company's fundamentals and long-term prospects. This mixed signal could lead to neutral short-term price movement as investors weigh the lowered price target against the reaffirmed positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100